Aligos Announces Phase 2a Topline Results of MASH Treatment ALG-055009
Aligos to release results from Phase 2a study of MASH therapy, ALG-055009, on September 19, 2024.
Aligos Therapeutics, Inc., a
biopharmaceutical company specializing in liver and viral disease treatments,
will announce topline results from the Phase 2a HERALD study of ALG-055009, a
thyroid hormone receptor beta (THR-β) agonist for treating
metabolic-dysfunction associated steatohepatitis (MASH). The announcement is
scheduled for Thursday, September 19, 2024, before the market opens.
Following the announcement, Aligos will host a conference
call and webcast at 8:30 am ET/5:30 am PT, featuring a slide presentation.
Participants can join via the Aligos website, where a replay will be available
for 90 days post-event.
Aligos Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on advancing best-in-class treatments for
liver and viral diseases, including MASH, hepatitis B, and coronaviruses. With
its strong R&D expertise, Aligos aims to address high unmet medical needs
in these areas.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Pharming Group Gains FDA Approval for Leniolisib in Children Aged 4–11 with APDS
Lonza Builds Oregon Spray-Drying Facility To Expand SDD Capacity
Discussion